Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment.

International clinical psychopharmacology - 1 May 2016

Su Yun-Ai, Li Ji-Tao, Dai Wen-Ji, Liao Xue-Mei, Dong Li-Cai, Lu Tian-Lan, Bousman Chad, Si Tian-Mei

Abstract excerpt

The serotonin system plays an important role in the pathogenesis of major depressive disorder (MDD) and genetic variations in serotonin-related genes affect the efficacy of antidepressants. The aim of this study was to investigate the relationship between genotypic variation in six candidate serotonergic genes (ADCY9, HTR1B, GNB3, HTR2A, TPH2, SLC6A4) and depressive and anxiety symptom severity trajectories as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenylyl Cyclases
Share to Antidepressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Citalopram

Share to Heterotrimeric GTP-Binding Proteins

Share to Pharmacogenomic Variants

Share to Receptor, Serotonin, 5-HT1B

Share to Receptor, Serotonin, 5-HT2A

Share to Tryptophan Hydroxylase

Source

Identifiers

PMID: 26745768
DOI: 10.1097/YIC.0000000000000115

Genes

TPH2
ADCY9
GNB3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment.PMID 26745768Read ↗

Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder.Semantic proximity Read ↗

Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response.Semantic proximity Read ↗

A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder.Semantic proximity Read ↗

Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis.Semantic proximity Read ↗

<em>5-HTR1A</em> and <em>5-HTR2A </em>genetic polymorphisms and SSRI antidepressant response in depressive Chinese patientsSemantic proximity Read ↗

DNA methylation of serotonin genes as predictive biomarkers of antidepressant treatment responseSemantic proximity Read ↗

Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment.Semantic proximity Read ↗

Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism.Semantic proximity Read ↗

Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study.Semantic proximity Read ↗

SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.Semantic proximity Read ↗

Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram.Semantic proximity Read ↗

Serotonin Pathway Polymorphisms and the Treatment of Major Depressive Disorder and Anxiety DisordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.